Bioject At The Forefront Of Product Development With Use Of Biojector(R) 2000 In Vical’s Expanded DNA Vaccine Clinical Trial

Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free injection therapy (NFIT) systems, announced the utilization of the Biojector(R) 2000 in Vical Inc.’s Phase 1 testing of its Vaxfectin? formulated plasmid DNA (pDNA) pandemic influenza vaccine, placing Bioject at the forefront of ongoing influenza vaccine research. [click link for full article]

More: continued here

Filed under: Clinical Trials on December 9th, 2007